International Journal of Gynecological Cancer最新文献

{"title":"Circulating tumor DNA in the diagnosis of ovarian cancer: a systematic review.","authors":"Cristina Taliento, Pantaleo Greco, Giulia Bruni, Ina Marie Dueholm Hjorth, An Coosemans, Wouter Froyman, Dirk Timmerman, John Charles Rotondo, Chiara Mazziotta, Martina Arcieri, Stefano Restaino, Francesco Multinu, Giuseppe Vizzielli, Carlotta Giorgi, Lars Dyrskjøt, Paolo Pinton, Giampaolo Morciano","doi":"10.1016/j.ijgc.2025.102686","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.102686","url":null,"abstract":"<p><strong>Objective: </strong>Ovarian cancer (OC) remains a leading cause of gynecologic cancer mortality worldwide, largely due to late-stage diagnosis and limited early detection tools. Circulating tumor DNA (ctDNA) has emerged as a promising non-invasive biomarker with the potential to improve diagnostic accuracy through detection of tumor-specific genetic and epigenetic alterations.</p><p><strong>Methods: </strong>This systematic review aimed to evaluate the diagnostic accuracy of ctDNA in detecting OC compared to healthy controls or benign conditions. A comprehensive literature search was conducted across PubMed, Web of Science, and EBSCO databases through April 2024, including studies that assessed sensitivity, specificity of ctDNA assays in plasma or serum samples. Risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 tool. PROSPERO registration number: CRD42024590089.</p><p><strong>Results: </strong>Nineteen studies met inclusion criteria, employing a variety of molecular techniques including polymerase chain reaction-based methylation assays (73.7%) and sequencing methods (whole genome sequencing/next-generation sequencing) (21%), targeting single genes or multi-gene panels. Diagnostic accuracy of ctDNA varied, with sensitivity (40.6%-94.7%) and specificity (56%-100%) ranging broadly, but often outperforming CA125, particularly in early-stage. Concordance between ctDNA and tumor tissue ranged from moderate (r = 0.428) to strong (r = 0.771).</p><p><strong>Conclusions: </strong>Although heterogeneity across studies precluded meta-analysis, narrative synthesis suggests that ctDNA may offer an improved early detection capability over CA125, through methylation and copy number variation analyses. Further controlled prospective studies are needed to validate the clinical utility of ctDNA as a complementary tool in OC detection.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"102686"},"PeriodicalIF":4.7,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145368020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methodological considerations for assessing laparoscopic tumor load as an independent prognostic marker in advanced ovarian cancer.","authors":"Li Zhou, Yindan Song","doi":"10.1016/j.ijgc.2025.102029","DOIUrl":"10.1016/j.ijgc.2025.102029","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"102029"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunotherapy in gynecologic clear cell carcinomas: moving beyond conventional approaches.","authors":"Mariana Carvalho Gouveia, Beatriz Devito Alencar de Oliveira, Leticia Vecchi Leis, Renata Colombo Bonadio, Mariana Scaranti","doi":"10.1016/j.ijgc.2025.102129","DOIUrl":"10.1016/j.ijgc.2025.102129","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 10","pages":"102129"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145064556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective long-term follow-up of sexuality and body image in women with primary vulvar cancer.","authors":"Diana Zach, Joanne de Hullu, Ivette Raices Cruz, Zuzana Kolkova, Johanna Sjöberg, Katja Stenström Bohlin, Angelique Flöter Rådestad","doi":"10.1016/j.ijgc.2025.102120","DOIUrl":"10.1016/j.ijgc.2025.102120","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the development of sexual activity, sexual function, and body image in women with primary vulvar cancer from the time of diagnosis to 24 months after the end of treatment.</p><p><strong>Methods: </strong>This nationwide prospective cohort study assessed health-related quality of life in women with newly diagnosed vulvar cancer using validated patient-reported outcome measures (EORTC-QLQ-VU34 [European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Vulva 34], Supportive Care Needs Survey Short Form) and self-constructed questions at diagnosis, and at 3, 12, and 24 months after the end of treatment. For this study, outcomes concerning sexuality and body image were analyzed. Results were displayed as mean scale scores and proportions. The longitudinal changes of scale and item scores were estimated by linear mixed-effects models with patient random intercept for continuous/numerical outcomes, and by generalized linear mixed models for binary response variables.</p><p><strong>Results: </strong>Between August 2019 and August 2021, 138 of 153 consenting women (90%) returned at least 1 questionnaire, and 90 women (59%) completed the questionnaires at all 4 time points. Sexual activity increased from 9.8% at diagnosis to 22.8% after 24 months (odds of being sexually active at 24 months were 6 times higher than at baseline, p = .003). Vulvar cancer was one of the reasons for not being sexually active for 37.5% of the participants at baseline and 26.9% at 24 months. Most women (73.5%) were not satisfied with their sex life at baseline. At least at one time point, 25.4% of the women found sex important, and 32.6% needed help with changes in sexual feelings. The mean scale scores of sexual functioning and body image did not change over time.</p><p><strong>Conclusions: </strong>Sexual activity was low, largely due to the vulvar cancer diagnosis. Most women were not satisfied with their sex life. A substantial proportion of the women found sex important and expressed a need for help with sexual feelings.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 10","pages":"102120"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Best original research presented at the 26th European Congress on Gynaecological Oncology: Best of ESGO 2025.","authors":"Houssein El Hajj, Joanna Kacperczyk-Bartnik, Nicolò Bizzarri, Andrej Cokan, Khayal Gasimli, Tanja Nikolova, Andrea Rosati, Esra Bilir, Tibor Andrea Zwimpfer, Martina Aida Angeles, Aleksandra Natalia Strojna, Valentina Ghirardi, Richard Tóth, David Viveros-Carreño, Ilker Kahramanoglu, Alexander Shushkevich, Anna Fagotti, Isabelle Ray-Coquard","doi":"10.1016/j.ijgc.2025.101932","DOIUrl":"10.1016/j.ijgc.2025.101932","url":null,"abstract":"<p><p>The Best of ESGO 2025 manuscript highlights a selection of the best original research presented at the 26th Congress of the European Society of Gynaecological Oncology (ESGO), held in Rome, Italy on February 20 to 23, 2025. Of the 1583 abstracts submitted, the ESGO scientific program committee chairs and authors from the European Network of Young Gynae Oncologists selected 32 high-impact studies for inclusion in this compilation. This included 15 best oral sessions abstracts, 8 mini oral sessions abstracts, 7 young investigator session abstracts, and 2 best 3-minute presentations abstracts. The key research themes this year included surgical optimization in primary and recurrent ovarian cancer, advances in immunotherapy and maintenance strategies for endometrial and cervical cancer, patient-centered outcomes and quality of life, biomarker-driven approaches for treatment personalization, novel screening and diagnostic tools, and emerging targeted therapies for rare or treatment-resistant sub-types. Through this publication, the ESGO and European Network of Young Gynae Oncologists aimed to promote awareness and visibility of the most promising advances in gynecologic oncology research among clinicians, researchers, patients, patient advocacy groups, and allied professionals across Europe and worldwide.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101932"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights from the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2025.","authors":"Letícia Vecchi Leis, Mariana Carvalho Gouveia, Jéssica Monteiro Vasconcellos, Mariana Scaranti","doi":"10.1016/j.ijgc.2025.102025","DOIUrl":"10.1016/j.ijgc.2025.102025","url":null,"abstract":"<p><p>The European Society for Medical Oncology Gynaecological Cancers Congress 2025, held in Vienna from June 19 to 21, brought together over 1150 participants from 82 countries to discuss recent advances in the management of gynecological cancers. With 17 scientific sessions and 126 abstract presentations, the congress served as a key platform for presenting innovations in the treatment of ovarian, cervical, uterine, vaginal, and vulvar cancers. This paper highlights and analyzes the most relevant studies presented, focusing on emerging treatment strategies, clinical trial outcomes, and translational research. By critically examining these contributions, we aim to provide a concise overview of the evolving landscape of gynecologic oncology and its implications for clinical practice.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 10","pages":"102025"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addition of metronidazole to standard-of-care perioperative prophylaxis at the time of hysterectomy for gynecologic malignancies.","authors":"Megan Gorman, Ariel Kredentser, Ioanna Agatha Katehis, Alejandro Alvarez, Annalese Williams, Jessica Silvestri, Antoinette Sakaris, Samantha Gobioff, Jeannine Villella, Jill S Whyte, Gary L Goldberg, Marina Frimer","doi":"10.1016/j.ijgc.2025.102036","DOIUrl":"10.1016/j.ijgc.2025.102036","url":null,"abstract":"<p><strong>Objective: </strong>The purpose of this study was to evaluate whether the combination of cefazolin or a second-generation cephalosporin plus metronidazole is associated with a reduced risk of surgical site infection in women undergoing hysterectomy for gynecologic cancer compared to using cefazolin or a second-generation cephalosporin alone.</p><p><strong>Methods: </strong>This was a retrospective cohort study of patients who underwent hysterectomy at a single institution between January 2020 and June 2022. The primary outcome was surgical site infection. All patients who underwent abdominal, robotic-assisted, or laparoscopic hysterectomy for presumed malignancy and received either a first- or second-generation cephalosporin with or without metronidazole, or gentamicin with clindamycin, were included in the analysis.</p><p><strong>Results: </strong>A total of 1055 patients were identified who underwent hysterectomy for malignancy during the study period across 4 hospital sites within our system. The overall rate of any surgical site infection was 3.2% (N = 34). Surgical site infection was found to be independently associated with diabetes (p < .01), smoking (p < .01), and antibiotic regimen (p = .04). Surgical site infection rates were 4.3% among patients treated with standard-of-care antibiotics and 2.1% with the addition of metronidazole. However, after adjusting for covariates using a mixed-effects binary logistic regression, the addition of metronidazole to standard-of-care antibiotics was not statistically significantly associated with a reduced risk of surgical site infection (OR 0.5, 95% CI 0.3 to 1.1).</p><p><strong>Conclusions: </strong>While there was evidence supporting an independent association between antibiotic regimen and surgical site infection rate, after adjusting for open incision, smoking status, and diabetes, there was no statistical difference in infection rates with the addition of metronidazole. Future studies with larger sample sizes are warranted to better elucidate these potentially important clinical effects.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 10","pages":"102036"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Laparotomic sentinel lymph node technique using Magtrace in early-stage ovarian cancer.","authors":"Pim Laven, Sandrina Lambrechts, Jochem van der Pol, Astrid Vernemmen, Brigitte Slangen, Roy Kruitwagen","doi":"10.1016/j.ijgc.2025.101743","DOIUrl":"10.1016/j.ijgc.2025.101743","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101743"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correspondence on \"Predictive factors for adnexal involvement in endometrial cancer FIGO stage IIIA\" by Dinoi et al.","authors":"Lijun Zhu, Yaowen Hu","doi":"10.1016/j.ijgc.2025.102023","DOIUrl":"10.1016/j.ijgc.2025.102023","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 10","pages":"102023"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144882841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes of external radiotherapy boost versus no boost to radiologically positive lymph nodes in FIGO stage IIIC cervical cancer.","authors":"Karthik S Rishi, K Harshita, Pilli Spandana, Pradeep Kumar Reddy Donapati, P S Hari, G V Giri","doi":"10.1016/j.ijgc.2025.102030","DOIUrl":"10.1016/j.ijgc.2025.102030","url":null,"abstract":"<p><strong>Objective: </strong>The management of lymph node-positive cervical cancer remains controversial, with limited data on outcomes following radiotherapy. In this retrospective study, we aimed to compare the clinical outcomes in patients who had received an additional boost to radiologically positive lymph nodes versus those who did not.</p><p><strong>Methods: </strong>A total of 231 patients with cervical cancer treated between January 2012 and December 2019 and identified as having radiologically positive lymph nodes were sorted into 2 groups: those who had received an external radiotherapy boost and those who had not. Sub-group analyses were performed based on lymph node size and number, as well as receipt of concurrent chemotherapy.</p><p><strong>Results: </strong>For patients with International Federation of Gynecology and Obstetrics stage IIIC cervical cancer, predominantly of the squamous sub-type, with a median age of 42.5 years (range; 33-85) and a median follow-up of 11 months (range; 3-119) the median disease-free and overall survival durations were 93 months (range; 6-120) and 84 months (range; 8-120), respectively. The median overall survival was higher in the group that had received an external radiation boost compared with those who had not (107 vs 91 months; P = .01). However, no overall survival benefit from a nodal boost was observed in patients with lymph nodes >2 cm or >4 positive nodes (105 vs 99 months, P = .048; 91 vs 73 months, P = .04, respectively). Concurrent chemotherapy improved median survival by 22 months (P = .023) in the nodal boost group.</p><p><strong>Conclusions: </strong>An external radiation boost was associated with improved overall survival in stage III cervical cancer, particularly in patients with fewer than 4 involved nodes, nodes <2 cm, and those receiving concurrent chemotherapy.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 10","pages":"102030"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}